CD8A and neoplasm: When investigated in a murine model of PDAC, Nintedanib reduced the tumour's vascular density and collagen content and interestingly, it induced a transformative shift in the desmoplastic and immune landscape, increasing the number of antitumour CD8+ T cells and reducing tumour-protecting FOXP3+ T cells.